Researchers close in on new melanoma gene

It has long been known that prolonged exposure to the suns harmful UV rays can lead to Melanoma, the deadliest form of skin cancer. An unanswered question, however, is why some people are more likely to develop melanoma than others. Despite years of research and clinical development, melanoma incidences continue to rise around the world. According to the National Cancer Institute, the percentage of people in the United States who develop melanoma each year has more than doubled in the past 30 years.

Results published today from a study led by researchers from The Translational Genomic Research Institute (TGen) in Phoenix, Arizona and The Queensland Institute of Medical Research (QIMR), Queensland, Australia, however, may yet change these statistics. The team is close to discovering a new gene that could help explain variation in melanoma risk.

In a report appearing in an Advance Online Publication (AOP) of the journal Nature Genetics, the researchers and their colleagues identify a region on chromosome 20 (20q11.22) that influences a person’s risk of developing melanoma.

According to Dr Kevin Brown, TGen Investigator and the paper’s co-first author, compared to other genetic research focusing on familial (or inherited) cases of melanoma, this finding holds implications for the general population

“We’re closing in on genetic variants which cause 16 percent of the population to be at nearly double the increased risk of developing the disease. In public health terms, this finding is highly significant,” Dr. Brown said.

The researchers narrowed the gene location through a genome-wide association study — a first in melanoma research. Genome-wide studies involve rapidly scanning DNA of many people to find genetic variations associated with a particular disease. After identifying new genetic associations, researchers can use the information to develop better strategies to detect, treat and prevent the disease.

“The aim of our work is to identify and understand the genetic factors influencing melanoma so we can better predict risk estimates,” said QIMR’s Dr. Stuart MacGregor, co-first author on the study. “This in turn, means people will be better informed and can take the right precautions to avoid developing this increasingly common cancer.”

How The Study Works
A genome-wide association study involves scanning the DNA from two sets of individuals: those with a particular disease (cases) and those of similar individuals without the disease (controls). The DNA of each sample then undergoes examination for strategically selected markers of genetic variation, called single nucleotide polymorphisms, or SNPs. If certain genetic variations are found to be significantly more frequent in people with the disease compared to people without disease, those variations are said to be "associated" with the disease. The associated genetic variations can serve as roadmaps to the region of the human genome where the disease-causing gene resides.

The study — whose data collection began 20 years ago — involved more than 4,000 Australian samples (2,019 cases and 2,105 controls) and was a joint project between Australian, American and European research groups.

Source: The Translational Genomics Research Institute

Related stories:

Inherited melanoma risk: What you do know does help you
When people know the results of genetic tests confirming they have inherited an increased risk of developing melanoma, they follow skin cancer screening recommendations more proactively—much like those who have already been diagnosed with the potentially deadly disease, according to results of a study completed at the University of Utah's Huntsman Cancer Institute. and published in the June issue of Cancer Epidemiology, Biomarkers & Prevention.
Report describes first targeted therapy to produce remission of metastatic melanoma
In a demonstration that even some of the most hard-to-treat tumors may one day succumb to therapies aimed at molecular "weak points," researchers at Dana-Farber Cancer Institute report the first instance in which metastatic melanoma has been driven into remission by a targeted therapy.
Defining cancer's genetic 'support network'
Researchers at Duke University’s Institute for Genome Sciences & Policy (IGSP) have developed a new method that essentially does for the genetic pathways underlying cancer what social networking web sites can do for people: It finds the connections among them.
Genome-wide survey nets key melanoma gene
One might call it a tale of two melanocytes. Given the same genetic mutation, why does one melanocyte shut down growth and become a relatively benign mole, while another rages out of control and develops into deadly melanoma?
Transparent fish to make human biology clearer
Zebrafish are genetically similar to humans and are good models for human biology and disease. Now, researchers at Children's Hospital Boston have created a zebrafish that is transparent throughout its life. The new fish allows scientists to directly view its internal organs, and observe processes like tumor metastasis and blood production after bone-marrow transplant in a living organism.
Gene signature spells poor outcome
Other than visually inspecting the disease, doctors have no genetic blueprint to classify melanomas, a lethal form of skin cancer. Tumors generally are ranked by how deeply the growth has invaded underlying skin tissue. The deeper it burrows into the skin, the more lethal the cancer, but some patients defy the odds and survive with thick tumors or die from thin ones.
Chromosomes tell tale of patient's risk for new, future cancer
Hodgkin's disease survivors who have greater genetic instability in their white blood cells are two-and-a-half times more likely to develop another type of cancer, researchers from The University of Texas M. D. Anderson Cancer Center report at the American Association for Cancer Research annual meeting in Los Angeles April 14-18.
Cancer researchers add spice to research against rare neuromuscular disease
Scientists who focus on the molecular signaling that underlies prostate cancer have discovered a compound that shows promise against a debilitating neurodegenerative condition known as Kennedy's disease, which is caused by a mutant gene. Currently there is no treatment for the inherited disorder, which resembles a slowly progressive form of Lou Gehrig's disease and affects only men.

News discussion:

Medicine & Health news